New York State Teachers Retirement System Sells 18,020 Shares of Hologic, Inc. (NASDAQ:HOLX)

New York State Teachers Retirement System decreased its position in Hologic, Inc. (NASDAQ:HOLX) by 8.9% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 185,321 shares of the medical equipment provider’s stock after selling 18,020 shares during the quarter. New York State Teachers Retirement System owned 0.08% of Hologic worth $11,447,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in HOLX. Norges Bank bought a new position in shares of Hologic in the fourth quarter worth about $133,414,000. Boston Partners lifted its stake in shares of Hologic by 81.0% during the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock valued at $257,959,000 after acquiring an additional 1,602,463 shares during the period. Champlain Investment Partners LLC acquired a new position in shares of Hologic during the fourth quarter valued at $79,291,000. Redwood Wealth Management Group LLC acquired a new stake in Hologic in the first quarter worth about $3,534,000. Finally, Northern Trust Corp raised its holdings in Hologic by 26.9% during the 4th quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider’s stock worth $226,898,000 after purchasing an additional 668,086 shares during the last quarter. 94.73% of the stock is owned by institutional investors.

Hologic Stock Down 0.9%

HOLX stock opened at $64.74 on Friday. The stock has a fifty day moving average of $60.58 and a 200-day moving average of $63.81. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.67. The company has a market capitalization of $14.43 billion, a price-to-earnings ratio of 27.31, a PEG ratio of 2.39 and a beta of 0.55. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.52 and a current ratio of 3.24.

Hologic (NASDAQ:HOLX) last issued its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same quarter last year, the business earned $1.03 earnings per share. The company’s quarterly revenue was down 1.2% on a year-over-year basis. As a group, equities research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

HOLX has been the subject of several analyst reports. Morgan Stanley lowered their price objective on Hologic from $77.00 to $65.00 and set an “equal weight” rating for the company in a research note on Monday, May 5th. Needham & Company LLC restated a “hold” rating on shares of Hologic in a research note on Tuesday, May 27th. Royal Bank Of Canada reduced their target price on shares of Hologic from $75.00 to $70.00 and set a “sector perform” rating for the company in a research note on Friday, May 2nd. Raymond James Financial reissued an “outperform” rating and set a $71.00 price target (down from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Finally, Evercore ISI reduced their price objective on shares of Hologic from $65.00 to $62.00 and set an “in-line” rating for the company in a research report on Friday, May 2nd. Twelve investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $77.42.

Insider Transactions at Hologic

In related news, Director Martin D. Madaus bought 5,445 shares of Hologic stock in a transaction on Wednesday, May 7th. The stock was acquired at an average price of $55.24 per share, with a total value of $300,781.80. Following the acquisition, the director directly owned 5,445 shares of the company’s stock, valued at $300,781.80. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.88% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.